Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
Mustang Bio, Inc. (MBIO)
Last mustang bio, inc. earnings: 11/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
mustangbio.com/investor-relations
Company Research
Source: GlobeNewswire
WORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2022. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “In 2022, we advanced our cell and gene therapy programs and presented promising research supporting the potential of our clinical portfolio at several prestigious medical meetings. Our lead clinical candidate is MB-106, a CD20-targeted, autologous CAR T cell therapy to treat relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic lymphocytic leukemia (“CLL”). MB-106 continues to generate compelling safety and efficacy data and remains attractive when compared to approved autol
Show less
Read more
Impact Snapshot
Event Time:
MBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBIO alerts
High impacting Mustang Bio, Inc. news events
Weekly update
A roundup of the hottest topics
MBIO
News
- Blastic Plasmacytoid Dendritic Cell Neoplasm Market Research and Forecast Report 2025-2035: CD123-Targeted Therapies Emerge as the Leading Opportunity, Driven by ADCs, CAR-T, Bispecific Development [Yahoo! Finance]Yahoo! Finance
- Mustang Bio (NASDAQ:MBIO) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Mustang Bio (NASDAQ:MBIO) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
MBIO
Sec Filings
- 12/23/25 - Form 8-K
- 12/3/25 - Form DEF
- 11/7/25 - Form 10-Q
- MBIO's page on the SEC website